What did @carcar_7171 actually say?
The creator says Wegovy is making her "way too tired" at week three, to the point her "eyes feel heavy" shortly after injecting. She also says it is "not really helping with weight loss" and she's considering switching to something else. These are two separate claims worth pulling apart.
The fatigue complaint is specific and time-stamped. She noticed it after this morning's injection and says it has not subsided across three weeks. The weight loss complaint is vaguer, but week three on the starting dose of 0.25 mg is almost universally too early to see meaningful scale movement. Those two issues deserve very different responses.
Does the science back this up?
On fatigue: yes, more than most providers acknowledge upfront. Clinical trial data consistently shows fatigue as a reported adverse event. In the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), fatigue was reported by roughly 11% of participants on semaglutide versus 4% on placebo. That is a real signal, not a nocebo effect.
The timing she describes, feeling it within hours of injecting, is also plausible. Semaglutide works partly through central nervous system pathways, including GLP-1 receptors in the brainstem that regulate energy balance. Activating those receptors can produce sedation-adjacent effects, particularly early in treatment when the body is not yet adapted. A 2022 review by Blundell et al. in Diabetes, Obesity and Metabolism noted that CNS-mediated effects of GLP-1 agonists include altered arousal and appetite signaling, which can manifest as fatigue in the short term.
On weight loss at week three: the starting dose of Wegovy (0.25 mg weekly) is a titration dose, not a therapeutic dose. Expecting meaningful fat loss this early is not supported by the pharmacology.
What did they get wrong (or right)?
She is mostly right about the fatigue being real, and deserves credit for tracking it precisely. But she conflates two separate problems into one conclusion: "my body's not liking it." That framing is where things get shaky.
Saying the drug "is not working" at week three on 0.25 mg is premature. The STEP trials reached full dosing (2.4 mg) over 16 to 20 weeks, and peak weight loss was observed at 68 weeks. Judging efficacy at week three is like leaving a movie after the opening credits. It is not a fair test.
She also implies that persistent fatigue means she is "somebody that it's not going to work for," which is not how GLP-1 response actually works. Non-responders exist, but they are identified by lack of weight loss at therapeutic doses over months, not by side effects at starter doses. Fatigue and efficacy are not the same axis.
What she got right: GLP-1 side effects do vary significantly between individuals. Some people tolerate semaglutide poorly and do better on tirzepatide or liraglutide. That instinct is not wrong. It just needs a clinician conversation, not a self-directed quit.
What should you actually know?
Fatigue on Wegovy is documented and underreported in patient education materials. If it is severe or lasting, that is a legitimate reason to contact your prescriber, not just push through. In some cases, the timing of the injection (morning versus evening) can shift when the fatigue hits, making it more manageable. Some patients find moving to an evening dose helps them sleep through the worst of it.
Three weeks is also not long enough to assess weight loss response on semaglutide. A 2022 analysis by Rubino et al. in JAMA found that clinically meaningful weight loss, defined as at least 5% body weight, typically begins emerging between weeks 12 and 20 at therapeutic doses. Week three at 0.25 mg is genuinely not a data point.
If fatigue does not resolve after dose titration, that is a different conversation. Persistent, debilitating fatigue warrants a clinical evaluation, including thyroid function, since GLP-1-related nausea and appetite suppression can occasionally mask other issues. Do not self-diagnose a treatment failure. Talk to a provider.
- Fatigue affects roughly 11% of semaglutide users per STEP 1 trial data
- CNS mechanisms of GLP-1 agonists can explain injection-proximate tiredness
- Week three at starter dose is too early to evaluate efficacy
- Individual variation in tolerability is real and worth a provider conversation
- Switching medications is a valid option, but should be a clinical decision